Clinical Trials Logo

Thoracic Tumors clinical trials

View clinical trials related to Thoracic Tumors.

Filter by:
  • None
  • Page 1

NCT ID: NCT06333951 Recruiting - Clinical trials for Non-small Cell Lung Cancer

AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)

Start date: June 3, 2024
Phase: Phase 1
Study type: Interventional

The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted thoracic tumors. The study also aims to determine the safety profile of AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted thoracic tumors.

NCT ID: NCT05165498 Not yet recruiting - Analgesia Clinical Trials

Real-time Ultrasound Guidance for Thoracic Epidural Blocks

Start date: July 2024
Phase:
Study type: Observational

Various modalities have been proposed for real-time confirmation of loss of resistance (LOR) for thoracic epidural blocks. With real-time ultrasound (US) guidance, the anesthesiologist attempts to visualize the sonographic advancement of the epidural needle and penetration of the epidural space (as detected by LOR) This observational study is set out to confirm the reliability of real-time ultrasound guidance as an adjunct to LOR for thoracic epidural blocks.

NCT ID: NCT04841538 Withdrawn - Clinical trials for Non-small Cell Lung Cancer

A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors

Start date: July 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, RP2D and PK/pharmacodynamic profile of ES101 monotherapy in patients with advanced NSCLC and to further evaluate the antitumor efficacy of ES101 in advanced malignant thoracic tumors, including NSCLC and SCLC.

NCT ID: NCT02941458 Recruiting - Thoracic Tumors Clinical Trials

Thoracic Tumours Register

RTT
Start date: July 21, 2016
Phase:
Study type: Observational [Patient Registry]

Observational, multicenter study in patients with lung cancer and other thoracic tumors. The GECP, in its commitment to improve the treatment and prognosis of patients with lung cancer and other thoracic tumors, has marked the individualization of treatment according to the expression of markers predictive of response to chemotherapeutic agents and molecular inhibitors of cell proliferation as one of its primary objectives. This could significantly improve the prognosis of patients with lung cancer, and will lead to a radical change in routine clinical practice. The aim of the register is to explore all data available of all patients treated because of thoracic tumours.